Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers ; volume:21 ; number:1 ; day:24 ; month:2 ; year:2022 ; pages:1-22 ; date:12.2022
Molecular cancer ; 21, Heft 1 (24.2.2022), 1-22, 12.2022
- Urheber
-
Kolesar, Jill
Peh, Spencer
Thomas, Levin
Baburaj, Gayathri
Mukherjee, Nayonika
Kantamneni, Raveena
Lewis, Shirley
Pai, Ananth
Udupa, Karthik S.
Kumar AN, Naveena
Rangnekar, Vivek M.
Rao, Mahadev
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-022-01534-8
- URN
-
urn:nbn:de:101:1-2022052619113932966412
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kolesar, Jill
- Peh, Spencer
- Thomas, Levin
- Baburaj, Gayathri
- Mukherjee, Nayonika
- Kantamneni, Raveena
- Lewis, Shirley
- Pai, Ananth
- Udupa, Karthik S.
- Kumar AN, Naveena
- Rangnekar, Vivek M.
- Rao, Mahadev
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Pharmacogenomics
NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
The pharmacogenomics journal
Pharmacogenomics and toxicogenomics
Pharmacogenomics and toxicogenomics
Clinical use of pharmacogenomics
Pharmacogenomics of neuropathic pain
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Status of Sentinel Lymph Node Biopsy in Gynecological Cancers
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Pharmacogenomics
NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
The pharmacogenomics journal
Pharmacogenomics and toxicogenomics
Pharmacogenomics and toxicogenomics
Clinical use of pharmacogenomics
Pharmacogenomics of neuropathic pain
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Status of Sentinel Lymph Node Biopsy in Gynecological Cancers
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Pharmacogenomics
NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
The pharmacogenomics journal
Pharmacogenomics and toxicogenomics
Pharmacogenomics and toxicogenomics
Clinical use of pharmacogenomics
Pharmacogenomics of neuropathic pain
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC